Companies

Judge approves Bayer's $7.25 billion Roundup settlement, ending most US cancer claims

A Missouri judge approved Bayer's settlement of up to $7.25 billion to resolve tens of thousands of US Roundup cancer lawsuits.

Key takeaways

  • Bayer (BAYRY) won court approval for a settlement of up to $7.25 billion to resolve tens of thousands of US lawsuits claiming its Roundup weedkiller causes cancer. Roughly 65,000 claims were covered, and the deal aims to resolve nearly all current and future US claims.
WallStreetBets logo

Key points

  • A Missouri judge approved Bayer's settlement of up to $7.25 billion to resolve tens of thousands of US Roundup cancer lawsuits.
  • Bayer had faced about 65,000 claims from people who said Roundup caused their cancer, and the deal aims to resolve nearly all current and future claims.
  • BAYRY shares closed down 0.13% on Nov. 20, while the ruling removes a major overhang on the German group.

A Missouri state judge approved Bayer's proposal to pay as much as $7.25 billion to resolve tens of thousands of US lawsuits claiming its Roundup weedkiller caused cancer. Judge Timothy Boyer of a state court in St Louis ruled on Friday that the settlement was "fair, reasonable and adequate."

The deal matters because it targets a legal burden that has weighed on the German company for close to a decade. The company had run into roughly 65,000 claims in state and federal courts across the US, brought by people who said Roundup, used at home or at work, had given them cancer. The settlement, first announced in February, aims to resolve nearly all current and future Roundup claims in the US.

The judge rejected complaints that individual cancer victims would receive too little, since earlier settlers had been paid more. He also said delays could force victims, including those with terminal cancer, to wait "an indeterminate number of years" to be paid.

Bayer's CEO, Bill Anderson, said in a statement that the approval was "a decisive milestone" in the company's strategy to mitigate the risks of both pending and future Roundup litigation.

The ruling came after an earlier setback for the plaintiffs. Five months earlier, the US Supreme Court threw out a $1.25 million jury verdict for John Durnell, a Missouri man who blamed glyphosate exposure for his non-Hodgkin lymphoma. By a 7-2 margin, the justices sided with Bayer, holding that a federal pesticide statute blocked failure-to-warn claims brought under state law, which removed a key foundation for many suits.

Christopher Seeger, who represents many of the plaintiffs, said the Durnell ruling made it harder for Roundup victims to take their cases to court. He said in a statement he looked forward to getting relief to all Roundup victims as quickly as possible.

Bayer's share price has fallen 46% since it bought Monsanto, which makes the weedkiller, for $63 billion in 2018. The company settled much of the Roundup litigation for $10.9 billion in 2020, but a $1.25 billion deal for future claims failed to win court approval.

The settlement excludes some lawsuits still pending in federal court. Bayer has said about 200 of those cases are still being litigated and that the Supreme Court decision gives it strong defenses. BAYRY shares closed down 0.13% on Nov. 20.

Sources: Bloomberg, Financial Times, The Guardian

Sources